Product Description
Mechanisms of Action: OPR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Austria | Belgium | Czech | Germany | Ireland | Luxembourg | Netherlands | Slovenia
Approved Indications: None
Known Adverse Events: None
Company: UZ Brussel
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Abdominal Pain|Pain, Postoperative
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2020-003682-19 | P3 |
Active, not recruiting |
Abdominal Pain|Pain, Postoperative |
2021-12-16 |